Cohort plc Stock
Price
Target price
€16.40
€16.40
9.330%
1.4
9.330%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cohort plc Stock
A very strong showing by Cohort plc today, with an increase of €1.40 (9.330%) compared to yesterday's price.
Pros and Cons of Cohort plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cohort plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cohort plc | 9.330% | 21.481% | 12.329% | -5.202% | 53.271% | 215.385% | 152.308% |
| Computacenter plc | 0.980% | 4.839% | -0.952% | 94.030% | 51.163% | - | - |
| Softcat plc | 0.000% | 7.619% | 6.604% | 23.497% | 40.373% | 40.373% | 10.784% |
| NCC Group plc | 0.690% | 5.072% | -13.174% | -10.494% | -8.805% | 31.818% | -59.497% |
News
Paragon Banking Group H1 Earnings Call Highlights
Paragon Banking Group (LON:PAG) reported what Chief Executive Nigel Terrington called “another strong financial and operational performance” for the first half of 2026, citing resilient margins
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
Key Points
- Interested in CG Oncology, Inc.? Here are five stocks we like better.
- Cohort CX data for cretostimogene plus gemcitabine showed a positive safety and efficacy signal in bladder
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears
CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for